MENLO PARK, Calif.,
Jan. 26, 2018 /PRNewswire/
-- BioPharmX Corporation (NYSE American: BPMX), a specialty
pharmaceutical company developing dermatology products, today
announced that a revolutionary technique to measure how effectively
a single dose of topically applied minocycline reached the
epidermis and pilosebaceous unit of human facial skin may
potentially explain early onset of efficacy observed in two
investigational BioPharmX drugs.
The measurement was accomplished using fluorescence lifetime
imaging microscopy (FLIM) to visualize the delivery of
BPX-011 for acne and BPX-041 for rosacea. The
specificity and sensitivity of the technique enabled researchers to
begin quantifying the local distribution of minocycline in a given
layer of skin. This research may open doors to using FLIM
technology to predict the efficacy of certain drugs and their
delivery early in the development process.
"This application of FLIM gives us the ability to assess the
effectiveness of drug delivery systems, introducing a new way of
carrying out pharmacokinetic studies." said Conor L. Evans, PhD, an Assistant Professor at
the Wellman Center for Photomedicine, Massachusetts General
Hospital, Harvard Medical School. "This
approach could significantly expand the utility of FLIM in the
development of new drugs."
Evans led one of the research teams presenting findings at SPIE
Photonics West, the world's largest multidisciplinary event for
photonics, Jan. 27 to Feb. 1 in
San Francisco.
"Innovative approaches such as the use of FLIM and other
nonlinear imaging microscopy could aid in advancing the
understanding of drug delivery, distribution, and metabolism, and
spur the development of pharmacokinetic and pharmacodynamic
tomography," said Kin F. Chan, PhD, Executive VP of R&D at
BioPharmX, Inc.
Research will be presented at three sessions:
- "Effects of endogenous fluorescence from ex vivo human facial
skin specimens in the pharmacokinetic study of a topical
minocycline gel using two-photon excitation fluorescence (2PEF) and
fluorescence lifetime imaging microscopy (FLIM)," paper 10475-16,
being presented at "Visualizing and Quantifying Drug Distribution
in Tissue II," on Jan. 27, from
3 p.m. to 3:20 p.m.
- "Phasor approach to fluorescence lifetime imaging microscopy
for visualization and quantification of drug distribution of a
topical minocycline gel in human facial skin," paper 10475-17,
being presented on Jan. 27, from
3:50 p.m. to 4:20 p.m.
- "Fluorescence lifetime imaging microscopy (FLIM) for
visualization of targeted drug delivery and local distribution in
skin of a single daily dose of topical minocycline gel: an update
on translational research from preclinical to clinical," paper
10467-15, being presented at "Photonics in Dermatology and Plastic
Surgery 2018," on Jan. 28, from
9 a.m. to 9:20 a.m.
BPX-01 is BioPharmX's investigational product for the treatment
of acne. It has successfully completed its phase 2b studies. BPX-04 is the company's
investigational product for the treatment of rosacea. It will begin
phase 2 studies soon. Both products share a novel delivery system
to carry a minocycline gel to the target area in the skin.
About BioPharmX Corporation
BioPharmX Corporation (NYSE American: BPMX) is a Silicon
Valley-based specialty pharmaceutical company, which seeks to
provide products through proprietary platform technologies for
prescription, over-the-counter (OTC), and supplement applications
in the health and wellness markets, including dermatology and
women's health. To learn more about BioPharmX,
visit www.BioPharmX.com.
Forward-Looking Statements
The information in this press release contains forward-looking
statements and information within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the "safe harbor" created by those sections. This press release
contains forward-looking statements about the company's
expectations, plans, intentions, and strategies, including, but not
limited to, statements regarding strategic partnering alternatives,
the safety and medical effects of BPX-04 and BPX-01, the effect
BPX-04 and BPX-01 may have on the treatment of rosacea and acne,
respectively, the commencement and results of future trials of
BPX-04 and BPX-01 and the size of such trials, continued and
consistent results in future tests of BPX-04 and BPX-01, absence of
side effects of future use of BPX-04 and BPX-01 and ability to
advance BPX-04 and BPX-01 through a successful NDA submission and
commercialization. These forward-looking statements may be
identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017 and our quarterly report on Form 10-Q for
the period ended July 31, 2017. Given
these risks and uncertainties, you are cautioned not to place undue
reliance on such forward-looking statements. The forward-looking
statements included in this news release are made only as of the
date hereof, and the company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
may be required under applicable securities law.
1 Caution: BPX-01 and BPX-04 are new drugs limited by
U.S. law to investigational use.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-data-on-new-fluorescence-lifetime-imaging-microscopy-to-measure-how-effectively-topically-applied-minocycline-reaches-targets-in-skin-300588440.html
SOURCE BioPharmX Corporation